What does hormone therapy actually do?
Hormone therapy is the most effective medical treatment for the symptoms most women find hardest to live with during the menopause transition.
Estrogen — taken alone if you have had a hysterectomy, or with a progestogen if your uterus is intact — typically reduces hot flash and night-sweat frequency by 75% or more.2211 It relieves the vaginal dryness, burning, and pain with sex that make up what clinicians call genitourinary syndrome of menopause (GSM; the umbrella term for vaginal and urinary symptoms caused by falling estrogen). It prevents bone loss and lowers the risk of fracture.
What HT is not: it is not a proven treatment for cognitive decline, and it is not a general anti-aging strategy. Those claims outrun the current evidence.
What was the WHI, and why did it cause so much fear?
In 2002, the Women's Health Initiative (WHI) — a large US trial of women taking combined estrogen-plus-progestin therapy — was stopped early and its results splashed across news headlines. Women stopped their prescriptions overnight. Prescriptions plummeted.
The numbers that caused the panic, in context: per 10,000 women-years on combined therapy (estrogen plus progestin), the WHI found 7 extra heart disease events, 8 extra strokes, 8 extra blood clots in the lungs (pulmonary emboli), and 8 extra invasive breast cancers — alongside 6 fewer colorectal cancers and 5 fewer hip fractures.33
What the headlines missed was the age of the women in the study. The average participant was 63 years old. Fewer than 10% were within 10 years of their final period. These were not the women clinicians were prescribing HT to in their 40s and early 50s for hot flashes. They were, in many cases, women who had been away from menopause for a decade or more.
A further follow-up published in 2017 — tracking WHI participants for 18 years — found no significant excess all-cause mortality, cardiovascular mortality, or cancer mortality with hormone therapy.55 The panic, in large part, had been driven by applying results from older women to younger ones.
What is the "timing hypothesis"?
The timing hypothesis is the single most important concept in the modern HT conversation.
Starting hormone therapy close to menopause — under age 60, or within 10 years of your final period — is associated with neutral-to-favorable cardiovascular outcomes. Starting it many years later, in women who are significantly older and whose arteries may already have developed early atherosclerosis (the buildup that precedes heart attacks), is associated with harm.
This is not a fringe position. The North American Menopause Society (NAMS) 2022 position statement,11 the Endocrine Society's 2015 clinical practice guideline,22 and the American Heart Association's 2020 statement all converge on the same framework: for most healthy symptomatic women under 60 or within 10 years of menopause, the risk-benefit calculation favors HT. Outside that window, it requires much more careful individual weighing.
The window matters. It is one of the key questions you and your clinician need to answer together.
What are the real risks — honestly?
The risks of HT are real. They are also smaller in absolute terms than many women believe, and they vary significantly depending on which type of therapy you take.
Breast cancer with combined therapy (estrogen plus progestogen):
This is the risk that receives the most attention, and it deserves the most honest accounting. A 2019 meta-analysis from the Collaborative Group on Hormonal Factors in Breast Cancer — pooling data from 58 epidemiologic studies covering roughly 108,000 women — found that five years of combined estrogen-plus-daily-progestogen therapy starting at age 50 increases 20-year breast cancer risk from 6.3% to 8.3%.66 That is an absolute increase of 2.0 per 100 women over 20 years — roughly 2 additional breast cancer cases per 1,000 women per year of use.
To state it plainly: for every 50 women taking combined HT for five years starting at age 50, the data suggest one additional breast cancer case over the following 20 years compared to women who took no HT.
That number is meaningful and should be part of your conversation. It is not a reason to refuse the discussion — but it is a real risk to weigh against real, sometimes significant, symptoms.
Estrogen alone (for women without a uterus):
Estrogen-only therapy carries a much smaller breast cancer signal — roughly 0.5 additional cases per 100 women over 20 years, or about 0.25 extra cases per 1,000 women per year.66 In the WHI's estrogen-alone arm, estrogen was actually associated with reduced breast cancer incidence over seven years of use.77
Blood clots (VTE) and stroke:
The risk of venous thromboembolism (VTE — blood clots in the legs or lungs) is higher with oral estrogen. Transdermal estrogen — patches, gels, sprays absorbed through the skin — does not appear to raise VTE risk in observational data,88 likely because it bypasses the liver and avoids the clotting-factor changes that oral estrogen produces. If you have risk factors for VTE (personal history, obesity, prolonged immobility), transdermal is typically the preferred route.
Endometrial cancer:
Taking estrogen alone in a woman who has a uterus raises the risk of cancer of the uterine lining (endometrial cancer). This is why a progestogen is added. With adequate progestogen use, this risk is essentially eliminated. This is not a risk for women who have had a hysterectomy.
Heart disease:
As the timing data above show, heart disease risk is neutral-to-favorable when HT is started under 60 or within 10 years of the final period. The concern applies to initiation much later — not to the window when most symptomatic women are making the decision.
Does the type of HT matter?
Yes — and in more ways than most people realize.
Progestogen type: Micronized progesterone (chemically identical to the progesterone your body makes) may have a more favorable breast-cancer and metabolic profile compared to synthetic progestins such as the medroxyprogesterone acetate (MPA) used in the original WHI trial. The evidence is largely observational, but it is consistent enough that it factors into clinical decision-making.
Route of estrogen: Transdermal estrogen (patches, gels, sprays) bypasses first-pass liver metabolism. Clinicians typically prefer it when there is concern about VTE risk, migraine with aura, high triglycerides, or gallbladder disease.
Vaginal-only options: For women whose primary concern is GSM — vaginal dryness, pain, or urinary symptoms — without significant hot flashes, low-dose vaginal estrogen, vaginal DHEA (prasterone), and ospemifene (a pill) are all effective options with minimal systemic absorption. These are typically considered safe even for women who cannot take systemic HT.
A word on "bioidentical" hormones: FDA-approved bioidentical products — meaning chemically identical to hormones the body produces — exist, are well-studied, and include estradiol patches, gels, and micronized progesterone. These are legitimate options. What is not equivalent is compounded "bioidentical" HRT, prepared by compounding pharmacies without FDA oversight. Compounded hormones are not standardized, their doses cannot be verified with the same rigor, and they are not endorsed by NAMS, the Endocrine Society, or ACOG. The word "bioidentical" is a chemistry term, not a safety guarantee.
Who should not take hormone therapy?
Some situations make systemic HT inappropriate, and it is important to know them.
Absolute contraindications — meaning HT is not an option:
- Current or recent estrogen-sensitive breast cancer
- Active or recent blood clot (VTE or pulmonary embolism)
- Active or recent stroke or heart attack
- Undiagnosed abnormal uterine bleeding
- Severe active liver disease
Relative contraindications — meaning it requires specialist discussion:
- High personal VTE risk (consider transdermal estrogen)
- Migraine with aura (consider transdermal estrogen)
- Uncontrolled high blood pressure
- Personal or family history of blood clots or certain cancers
If any of these apply to you, the conversation with your clinician becomes more complex — not necessarily a no, but one that needs specialist input.
How do I think through the decision?
There is no algorithm that spits out the right answer. But there is a useful set of questions to bring to your clinician:
- What are your most disruptive symptoms? Hot flashes, night sweats, disrupted sleep, GSM, or mood — HT addresses these. Cognitive decline or "anti-aging" goals — HT does not.
- How old are you, and how long ago was your final period? This determines whether you are inside the window where the risk-benefit math is most favorable.
- Do you have a uterus? If yes, you need a progestogen alongside estrogen.
- What is your personal risk profile? VTE history, breast cancer family history, cardiovascular risk factors, and liver health all shape the conversation.
- What route makes sense for you? Oral, transdermal, vaginal — each has trade-offs.
- Plan to reassess annually. The right decision at 51 may not be the right decision at 60. Needs and risks change.
The goal of this framework is to walk into that appointment with the right questions, not to walk away from it with a decision made by a website.